These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20822716)

  • 21. Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis.
    Montes A; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Rheum; 2012 Oct; 64(10):3102-10. PubMed ID: 22674012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.
    Vossenaar ER; Després N; Lapointe E; van der Heijden A; Lora M; Senshu T; van Venrooij WJ; Ménard HA
    Arthritis Res Ther; 2004; 6(2):R142-50. PubMed ID: 15059278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis.
    Malakoutikhah M; Gómara MJ; Gómez-Puerta JA; Sanmartí R; Haro I
    J Med Chem; 2011 Nov; 54(21):7486-92. PubMed ID: 21981664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicentric reticulohistiocytosis with positive anticyclic citrullinated antibodies.
    Chauhan A; Mikulik Z; Hackshaw KV
    J Natl Med Assoc; 2007 Jun; 99(6):678-80. PubMed ID: 17595939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.
    Brink M; Hansson M; Mathsson L; Jakobsson PJ; Holmdahl R; Hallmans G; Stenlund H; Rönnelid J; Klareskog L; Rantapää-Dahlqvist S
    Arthritis Rheum; 2013 Apr; 65(4):899-910. PubMed ID: 23310951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis.
    Iwaszkiewicz C; Puszczewicz M; Białkowska-Puszczewicz G
    Int J Rheum Dis; 2015 Jan; 18(1):46-51. PubMed ID: 25488711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.
    Ytterberg AJ; Joshua V; Reynisdottir G; Tarasova NK; Rutishauser D; Ossipova E; Haj Hensvold A; Eklund A; Sköld CM; Grunewald J; Malmström V; Jakobsson PJ; Rönnelid J; Padyukov L; Zubarev RA; Klareskog L; Catrina AI
    Ann Rheum Dis; 2015 Sep; 74(9):1772-7. PubMed ID: 24817415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis.
    Russell AS; Devani A; Maksymowych WP
    J Rheumatol; 2006 Jul; 33(7):1240-2. PubMed ID: 16724377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of anticyclic citrullinated peptide antibody in rheumatoid arthritis.
    Jansen TL; Bruyn GA
    J Rheumatol; 2004 May; 31(5):1012-3; author reply 1013. PubMed ID: 15124273
    [No Abstract]   [Full Text] [Related]  

  • 38. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
    van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
    Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis.
    Walscheid K; Hennig M; Heinz C; Wasmuth S; Busch M; Bauer D; Dietzel M; Deeg CA; Heiligenhaus A
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(6):3447-53. PubMed ID: 24764059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.
    Payet J; Goulvestre C; Bialé L; Avouac J; Wipff J; Job-Deslandre C; Batteux F; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2014 Dec; 41(12):2395-402. PubMed ID: 25274898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.